LabCorp, a leading global life sciences company, announced that its Covance Drug Development business entered into a strategic technology agreement with GlaxoSmithKline plc (GSK).
With the 2018 theme #PressForProgress, a Panel of HBA leaders was assembled to share practical examples of how they have leveraged their HBA experience — what they have learned and the relationships they have developed — to move the needle in their own careers and enhance their organization’s performance.
Dr. Henry Li, a respected expert in preclinical pharmacology, will present a webinar showing data derived from CrownBio’s large-scale immunotherapy screening platform, MuScreen.
Pfizer Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions recommending that two Pfizer hematology medicines be granted marketing authorizations in the European Union.
AstraZeneca and Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending a marketing authorization of Lynparza (olaparib) tablets (300 mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy.
Shire plc announced the U.S. Food and Drug Administration accepted the Biologics License Application and granted priority review for lanadelumab (SHP643).
Beacon Healthcare Communications named Amy Whitcomb as Director of Multi-Channel Marketing in response to growing client needs for integrated multi-channel marketing solutions to drive brand campaign performance.
Huntsworth plc announced the acquisition of New York-based AboveNation Media LLC, adding to its collection of leading health, wellness and lifestyle marketing companies under Evoke Group.
Ashfield, part of UDG Healthcare, a global leader in providing outsourced healthcare services, announced the launch of a pioneering new commercial model called The Ashfield Solution.
Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders
Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Biotechnology, Central Nervous System, CNS Disorders, Collaboration, Duchenne Muscular Dystrophy (DMD), Frontotemporal Dementia (FTD), Genes, Huntingtin (HTT) Gene, Huntington’s disease, Issue Archives, Parkinson’s disease, Spinocerebellar Ataxia Type 3 (SCA3)Wave Life Sciences Ltd. announced the formation of a global strategic collaboration with Takeda Pharmaceutical Company Ltd. to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system.
